Simple benchmark for complex dose finding studies
From MaRDI portal
Publication:5170208
DOI10.1111/biom.12158zbMath1419.62325OpenAlexW2168881814WikidataQ40819161 ScholiaQ40819161MaRDI QIDQ5170208
Publication date: 22 July 2014
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/biom.12158
efficacycombination therapyphase I trialsutility scoresmultiple toxicitiesphase I/II trialstoxicity tradeoff
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Related Items
Patient-specific dose finding in seamless phase I/II clinical trials ⋮ A new design of the continual reassessment method ⋮ A continual reassessment method without undue risk of toxicity
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Adaptive designs for dose-finding based on efficacy-toxicity response
- Dose-Finding Designs for HIV Studies
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Coherence principles in dose-finding studies
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Sequential Implementation of Stepwise Procedures for Identifying the Maximum Tolerated Dose
- A Random Walk Rule for Phase I Clinical Trials
- Statistical Methods for Rates and Proportions
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
- Non-parametric optimal design in dose finding studies
